Literature DB >> 27665475

Cancer nanotheranostics: Strategies, promises and impediments.

Moumita Roy Chowdhury1, Canan Schumann2, Dipita Bhakta-Guha3, Gunjan Guha4.   

Abstract

Cancer has remained one of the most indomitable conundrums for scientists over centuries due to its multifarious etiology. While improved therapeutic and diagnostic approaches have commendably augmented the rate of survival of cancer patients, a holistic riddance from the ailment is still implausible. Hence, further explorations to scout for novel strategies of cancer therapy and diagnosis are necessary. Theranostics (amalgamation of therapy and diagnostics) has emerged as one of the avant-garde strategies, which provides a two-pronged advantage in cancer management. This integrative approach has found immense relevance in light of nanotechnology. Nanoparticles can be customized (loaded with a mélange of therapeutic drugs and diagnostic probes) to develop theranostic properties, thereby constructing nanotheranostic agents. These nano-composites are lucrative tools for cancer cell obliteration and simultaneous monitoring of the drug action, and can also be tailored for targeted drug delivery. Nanotheranostic agents have emerged as a prudent ploy for synchronized cancer intervention and detection of the 'route and reach' of the drugs. In this review, we discuss the diversified state-of-the-art facets of theranostic nanoparticles, including various nanoparticle-based platforms as well as the plethora of reported therapeutic drugs, aptamers, markers and diagnostic molecules that have found use in the precincts of nanotheranostics.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cancer; Diagnosis; Nanoparticle; Nanotheranostics; Theranostics; Therapy

Mesh:

Substances:

Year:  2016        PMID: 27665475     DOI: 10.1016/j.biopha.2016.09.035

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  11 in total

Review 1.  Recent advances in porphyrin-based nanocomposites for effective targeted imaging and therapy.

Authors:  Navid Rabiee; Mohammad Tavakkoli Yaraki; Soha Mokhtari Garakani; Shima Mokhtari Garakani; Sepideh Ahmadi; Aseman Lajevardi; Mojtaba Bagherzadeh; Mohammad Rabiee; Lobat Tayebi; Mohammadreza Tahriri; Michael R Hamblin
Journal:  Biomaterials       Date:  2019-12-18       Impact factor: 12.479

Review 2.  Theranostic Nanoparticles for Tracking and Monitoring Disease State.

Authors:  Cristina Zavaleta; Dean Ho; Eun Ji Chung
Journal:  SLAS Technol       Date:  2017-11-08       Impact factor: 3.047

3.  Versatility of targeted antibiotic-loaded gold nanoconstructs for the treatment of biofilm-associated bacterial infections.

Authors:  Daniel G Meeker; Tengjiao Wang; Walter N Harrington; Vladimir P Zharov; Sarah A Johnson; Samir V Jenkins; Stephanie E Oyibo; Christopher M Walker; Weston B Mills; Mark E Shirtliff; Karen E Beenken; Jingyi Chen; Mark S Smeltzer
Journal:  Int J Hyperthermia       Date:  2018-03       Impact factor: 3.914

4.  Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields.

Authors:  Tiffanie S Stewart; Abhignyan Nagesetti; Rakesh Guduru; Ping Liang; Emmanuel Stimphil; Ali Hadjikhani; Luis Salgueiro; Jeffrey Horstmyer; Renzhi Cai; Andrew Schally; Sakhrat Khizroev
Journal:  Nanomedicine (Lond)       Date:  2018-01-18       Impact factor: 5.307

5.  A biophysical study on the mechanism of interactions of DOX or PTX with α-lactalbumin as a delivery carrier.

Authors:  Behdad Delavari; Fatemeh Mamashli; Bahareh Bigdeli; Atefeh Poursoleiman; Leila Karami; Zahra Zolmajd-Haghighi; Atiyeh Ghasemi; Samaneh Samaei-Daryan; Morteza Hosseini; Thomas Haertlé; Vladimir I Muronetz; Øyvind Halskau; Ali Akbar Moosavi-Movahedi; Bahram Goliaei; Ali Hossein Rezayan; Ali Akbar Saboury
Journal:  Sci Rep       Date:  2018-11-26       Impact factor: 4.379

Review 6.  The Role of Magnetic Nanoparticles in Cancer Nanotheranostics.

Authors:  Maria Ferreira; João Sousa; Alberto Pais; Carla Vitorino
Journal:  Materials (Basel)       Date:  2020-01-07       Impact factor: 3.623

7.  TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.

Authors:  Efthymia-Iliana Matthaiou; Yi Guo; Jaleh Barar; Raphael Sandaltzopoulos; Lana E Kandalaft; Chunsheng Li; George Coukos; Yadollah Omidi
Journal:  Bioimpacts       Date:  2021-12-19

8.  Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts.

Authors:  Stephanie J Blocker; Kirk A Douglas; Lisa Anne Polin; Helen Lee; Bart S Hendriks; Enxhi Lalo; Wei Chen; Anthony F Shields
Journal:  Theranostics       Date:  2017-09-26       Impact factor: 11.556

9.  The theranostic efficiency of tumor-specific, pH-responsive, peptide-modified, liposome-containing paclitaxel and superparamagnetic iron oxide nanoparticles.

Authors:  Xiu-Chai Zheng; Wei Ren; Shuang Zhang; Ting Zhong; Xiao-Chuan Duan; Yi-Fan Yin; Mei-Qi Xu; Yan-Li Hao; Zhan-Tao Li; Hui Li; Man Liu; Zhuo-Yue Li; Xuan Zhang
Journal:  Int J Nanomedicine       Date:  2018-03-13

Review 10.  Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme.

Authors:  L Nam; C Coll; L C S Erthal; C de la Torre; D Serrano; R Martínez-Máñez; M J Santos-Martínez; E Ruiz-Hernández
Journal:  Materials (Basel)       Date:  2018-05-11       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.